Global Allergy Treatment Market Outlook, 2030

Historically, allergy treatments began with basic interventions in the early 20th century, such as allergen immunotherapy, and gradually expanded to include antihistamines, corticosteroids, and later, biologics. In recent years, innovative therapies like monoclonal antibodies have transformed the treatment landscape by targeting underlying immune responses, offering more effective management of conditions such as allergic rhinitis, asthma, and food allergies. The demand for allergy treatments continues to increase due to factors such as urbanization, environmental pollution, and changing lifestyles, which contribute to higher incidence rates worldwide. The increased cost of aimed therapies, particularly allergen immunotherapies and monoclonal antibodies, limits their adoption across middle- and low-income economies. Additionally, the authorization and commercialization of monoclonal antibodies (e.g., omalizumab and dupilumab) are revolutionizing treatment strategies, especially in atopic dermatitis and moderate-to-severe allergic asthma. For instance, in 2024, Sanofi and Regeneron’s Dupixent received increased approval for chronic spontaneous urticaria in the European Union, offering new revenue pathways in chronic allergy care and contributing to the biologics segment’s market expansion. Although there is improved clinical efficiency, the affordability gap persists to restrict accessibility, especially in regions with limited insurance coverage. Allergy treatment market penetration and long-term adherence among patients is being impacted obstructing uniform growth across the global market. For instance, the annual cost of biologic treatment for acute asthma can exceed $30,000 in the U.S., making it inaccessible to a substantial portion of patients without comprehensive reimbursement schemes or private insurance. Regulatory oversight plays a critical role in this market, with agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) ensuring that treatments meet stringent safety and efficacy standards, supported by compliance with Good Manufacturing Practices (GMP) and necessary certifications.

According to the research report “Global Allergy Treatment Market Outlook, 2030” published by Bonafide Research, the global Allergy Treatment market is projected to reach market size of USD 45.58 Billion by 2030 increasing from USD 32.08 Billion in 2024, growing with 6.16% CAGR by 2025-30.Rapid urbanization, increasing air pollution, changes in dietary habits, and climate change have contributed to heightened exposure to allergens, prompting greater demand for effective treatments. Technological advancements have further bolstered market growth, with innovations such as biologics, monoclonal antibodies, and advanced immunotherapy offering targeted and more efficient solutions compared to conventional antihistamines and corticosteroids. These advanced therapies not only improve patient outcomes but also open new revenue streams for pharmaceutical companies. Surge in number of people diagnosed with severe cases of allergies is augmenting the demand for effective treatment options. This is prompting pharmaceutical firms to invest continuously in research and development of advanced methods, diagnostic tools, and preventive measures. According to the Global Allergy and Airways Patient Platform, there has been an increase in cases of allergic conditions and severe reactions, with an estimated 30% to 40% of the world population suffering from one or more allergic conditions. According to data published by WebMD, seasonal allergies cost the U.S. healthcare system and businesses about U.S. 20 Bn annually in expenditure, treatment, and lost productivity. Similarly, according to a recent survey published by the European Medicine Agency in September 2023, the adoption of Palforzia in European region is lower than the expected post drug launch. As a significant development in the market, Nestlé divested its Palforzia business in September 2023 to Stallergenes Greer, a biopharmaceutical company specializing in allergy diagnosis and treatment. This strategic move followed Nestlé's earlier announcement of a review of Palforzia, with Nestlé set to receive milestone payments and ongoing royalties from Stallergenes Greer as part of the agreement.

Market Drivers

• Rising Prevalence of Allergic Diseases: The global allergy treatment industry is being significantly propelled by the increasing incidence of allergic conditions such as asthma, allergic rhinitis, atopic dermatitis, and food allergies. Rapid urbanization, environmental pollution, and changes in lifestyle, particularly in developing countries, have triggered a surge in allergic responses. Additionally, increased awareness among patients and caregivers regarding early diagnosis and management has led to higher healthcare-seeking behavior, boosting demand for allergy diagnostics, medications, immunotherapy, and preventive treatments. Pharmaceutical companies are responding by introducing advanced biologics, combination therapies, and innovative drug delivery systems, further supporting market growth.
• Technological Advancements and Innovative Therapies: Innovations in allergy treatment, such as sublingual and subcutaneous immunotherapy, targeted biologics, and precision medicine, are driving market expansion. These treatments are increasingly preferred over traditional antihistamines and corticosteroids due to higher efficacy, reduced side effects, and improved patient compliance. Furthermore, the development of digital health tools, mobile apps for symptom tracking, and telemedicine platforms has enhanced accessibility and treatment adherence. Investments in R&D for novel vaccines and personalized therapies are strengthening the industry’s growth trajectory, making treatment more patient-centric and outcomes-focused.

Market Challenges

• High Cost of Advanced Treatments: While innovative therapies like biologics and immunotherapies are highly effective, their high cost poses a significant barrier to widespread adoption, particularly in emerging economies. Many patients cannot afford long-term treatments, and insurance coverage for these therapies is often limited. This affordability issue restricts market penetration, slows adoption of cutting-edge treatments, and compels companies to balance pricing strategies with innovation. Additionally, cost pressures can impact healthcare providers’ ability to offer these treatments, particularly in public health settings.
• Lack of Awareness and Diagnostic Gaps: Despite rising prevalence, a large segment of the global population remains underdiagnosed or misdiagnosed due to limited awareness of allergy symptoms, inadequate diagnostic infrastructure, and variations in healthcare access. Misdiagnosis can lead to ineffective treatment or symptom worsening. Furthermore, insufficient training of healthcare professionals in allergy management in some regions hampers early intervention. These gaps create a challenge for the market, as the full potential of allergy treatments cannot be realized without accurate diagnosis and patient education.

Market Trends

• Shift Towards Personalized Medicine: The allergy treatment market is witnessing a clear shift towards personalized medicine, where therapies are tailored according to a patient’s genetic makeup, immune profile, and environmental exposures. Precision approaches such as biologics targeting specific immune pathways, allergy vaccines, and gene-based interventions are gaining traction. This trend is supported by advancements in molecular diagnostics, biomarker identification, and predictive analytics, which allow clinicians to design individualized treatment plans with better efficacy and reduced adverse effects.
• Growth of Over-the-Counter (OTC) Treatments and Self-Care Products: There is a rising consumer preference for self-care and over-the-counter allergy remedies, including antihistamines, nasal sprays, eye drops, and herbal supplements. This trend is fueled by greater health awareness, digital marketing, and e-commerce platforms, which make these products easily accessible. OTC availability allows patients to manage mild symptoms independently while reducing the burden on healthcare facilities. However, it also emphasizes the need for proper guidance to prevent misuse or delayed medical consultation for severe allergies.

Food allergies lead the global allergy treatment industry due to their rising prevalence, potentially severe health impacts, and growing awareness driving demand for specialized therapies.

Food allergies have become the leading type in the global allergy treatment industry primarily because of the increasing prevalence of these conditions, coupled with their potentially life-threatening consequences and growing public awareness. Globally, factors such as urbanization, changes in dietary habits, environmental exposures, and genetic predisposition have contributed to a significant rise in food allergies, especially among children, but increasingly among adults as well. Common allergens like peanuts, tree nuts, milk, eggs, shellfish, and wheat are responsible for severe allergic reactions, including anaphylaxis, which can be fatal if not treated promptly. This high risk associated with food allergies drives the need for effective treatments, emergency interventions like epinephrine auto-injectors, and long-term management solutions such as oral immunotherapy and allergy desensitization programs. Another critical factor is the growing consumer and regulatory awareness around food labeling and safety standards, particularly in developed regions like North America and Europe, which further underscores the need for preventive and therapeutic solutions. Parents, caregivers, and patients increasingly demand access to specialized treatments, diagnostic tests, and patient education to manage these conditions safely, creating a robust market for allergy treatment products. Pharmaceutical companies have responded by developing targeted therapies, including novel biologics that modulate immune responses, as well as formulations that reduce the risk of severe allergic reactions, thereby expanding the product portfolio and market size. Additionally, rising awareness campaigns, advocacy by patient organizations, and digital health platforms that educate and support individuals with food allergies have amplified the visibility of this allergy type, encouraging early diagnosis and adherence to treatment protocols.

Anti-allergy drugs lead the global allergy treatment industry due to their wide accessibility, effectiveness in managing multiple allergy types, and high patient preference.

Anti-allergy drugs are the leading treatment type in the global allergy treatment industry because they offer fast, effective, and accessible solutions for managing a broad spectrum of allergic conditions, including seasonal and perennial rhinitis, asthma, food allergies, and skin-related allergies. These drugs, which include antihistamines, corticosteroids, decongestants, leukotriene receptor antagonists, and combination therapies, are widely recognized for their ability to provide symptomatic relief and improve quality of life, making them the first choice for patients and healthcare providers alike. The convenience of oral, nasal, and topical formulations ensures patient compliance, while the over-the-counter availability of many antihistamines expands access beyond clinical settings, allowing individuals to manage mild to moderate symptoms independently. The growing prevalence of allergic diseases globally, fueled by urbanization, environmental pollution, and lifestyle changes, has further driven demand for anti-allergy drugs, positioning them as a critical component of everyday healthcare. Additionally, continuous research and development have led to the introduction of newer-generation antihistamines and biologically enhanced drugs with fewer side effects, longer duration of action, and improved efficacy, reinforcing their market dominance. Healthcare professionals often prefer prescribing anti-allergy drugs due to their predictable outcomes and ease of integration into treatment plans, which enhances patient trust and adherence. Furthermore, awareness campaigns, public health initiatives, and digital health tools have educated patients on the importance of timely intervention, further boosting demand for these medications.

Tablets and capsules lead the global allergy treatment industry due to their convenience, ease of administration, accurate dosing, and widespread patient acceptance.

Tablets and capsules dominate the global allergy treatment industry because they provide a convenient, safe, and highly effective method for delivering a wide range of anti-allergic medications. These dosage forms, which include antihistamines, corticosteroids, leukotriene inhibitors, and combination therapies, are particularly favored due to their portability, ease of administration, and accurate dosing, making them suitable for both adults and pediatric populations. Patients can easily incorporate tablets and capsules into their daily routines, enhancing treatment adherence, which is crucial in managing chronic and seasonal allergic conditions such as allergic rhinitis, asthma, and food allergies. The stability and long shelf life of these solid oral dosage forms also make them ideal for distribution and storage, supporting large-scale manufacturing, global supply chains, and accessibility in urban and rural areas alike. Another factor driving the popularity of tablets and capsules is their cost-effectiveness; they are generally less expensive to produce compared to advanced delivery systems such as injectables or nasal sprays, which allows for wider availability in both developed and developing markets. Pharmaceutical companies continuously innovate within this format, introducing fast-dissolving tablets, extended-release capsules, and combination formulations that enhance therapeutic efficacy while minimizing side effects. Furthermore, tablets and capsules are often preferred by healthcare providers due to their predictable pharmacokinetics, ensuring consistent absorption and reliable symptom control for patients. The growing prevalence of allergies worldwide, particularly in North America and Europe, has further fueled demand for these dosage forms, as patients seek safe, efficient, and easy-to-use treatment options.

Retail pharmacies lead the global allergy treatment industry due to their wide accessibility, convenience, and ability to provide both prescription and over-the-counter allergy medications.

Retail pharmacies dominate the global allergy treatment industry because they offer unparalleled accessibility and convenience for patients seeking quick and reliable allergy relief. These outlets serve as the primary point of contact between consumers and allergy medications, providing both prescription drugs, such as corticosteroids and leukotriene inhibitors, and over-the-counter treatments, including antihistamines, decongestants, and combination therapies. The extensive network of retail pharmacies across urban, suburban, and even semi-urban areas ensures that patients can easily access necessary medications without traveling long distances or navigating complex healthcare systems. Convenience is further enhanced by extended operating hours, online ordering platforms, and home delivery services offered by many retail chains, which cater to the increasing demand for quick and hassle-free access to treatment. Retail pharmacies also play a critical role in patient education, with trained pharmacists offering guidance on drug usage, dosage, potential side effects, and interactions with other medications, which promotes proper adherence and enhances treatment outcomes. Additionally, retail pharmacies are strategically positioned to capitalize on the rising prevalence of allergic diseases globally, including allergic rhinitis, asthma, food allergies, and atopic dermatitis, by offering a wide portfolio of products from leading pharmaceutical manufacturers. Their role in over-the-counter sales is particularly significant, as many allergy sufferers prefer self-medication for mild or seasonal symptoms, avoiding the need for a doctor’s visit while still receiving professional advice when needed.

North America leads the global allergy treatment industry primarily due to advanced healthcare infrastructure, high prevalence of allergic disorders, and significant investments in research and development.

North America has emerged as the dominant region in the global allergy treatment industry because of a combination of epidemiological, technological, and economic factors. The region has one of the highest prevalence rates of allergic conditions such as asthma, allergic rhinitis, atopic dermatitis, and food allergies, driven by lifestyle factors, urbanization, environmental pollution, and genetic predispositions. This high disease burden creates a substantial and consistent demand for both prescription and over-the-counter allergy treatments, including antihistamines, corticosteroids, immunotherapies, and biologics. Moreover, the region benefits from a well-established and sophisticated healthcare infrastructure, characterized by advanced hospitals, specialized allergy clinics, and easy access to diagnostic tools, which facilitate timely diagnosis and treatment. North America also leads in terms of pharmaceutical innovation and R&D investment, with several multinational companies headquartered in the United States and Canada actively developing new therapies, including biologics and precision medicine approaches, to address complex and severe allergic conditions. Regulatory support from agencies such as the U.S. Food and Drug Administration (FDA) ensures that innovative therapies can reach the market efficiently while maintaining stringent safety standards, further encouraging industry growth. Additionally, high healthcare expenditure and strong insurance coverage across the region enable patients to afford both conventional and advanced treatments, including expensive immunotherapies and novel biologics, which are often cost-prohibitive in other regions. Public awareness regarding allergies is also significantly higher, with extensive educational campaigns, patient advocacy groups, and professional societies promoting early diagnosis and treatment adherence.

• In April 2024, ImmunoNext entered a strategic partnership with Charité – Universitätsmedizin Berlin to develop a multi-sensitization allergy diagnostic platform by using digital biomarker profiling. This aligns with rising industry trends toward personalized immunotherapy and precision diagnostics in allergy care.
• In February 2024, ALK-Abelló A/S launched next-generation sublingual immunotherapy (SLIT) tablets across the U.S. and Japan for dust mite and pollen allergies. This product launch reflects shifting preferences from injectable to oral immunotherapy formats in regulated markets and supports improved patient compliance.
• In May 2024, Johnson & Johnson's Janssen initiated clinical trials for a novel monoclonal antibody targeting dual allergic pathways (IL-13/TSLP), addressing comorbid asthma and allergic rhinitis. reflecting a growing market strategy of targeting multiple allergic responses through biologics for long-term disease control.
• In February 2024, Genentech, a prominent pharmaceutical company, announced that its novel anti-allergy injection called Xolair had received U.S. Food and Drug Administration (FDA) approval for severe allergy treatment caused by exposure to certain food. The drug has been approved for usage in adults and children above the age of one.
• In October 2023, Astria Therapeutics, Inc announced a license agreement with Inchon’s Sciences. The agreement covers the OX40 portfolio, particularly focusing on development of STAR-0310 for potential treatment of atopic dermatitis (AD) and other allergic and immunological diseases.
• In January 2023, ALK received FDA approval for expanded use of ODACTRA, a sublingual immunotherapy tablet in the treatment of house dust mite-induced allergic rhinitis for adolescents aged 12 through 17. Show more